

## MAIL STOP AFTER FINAL Attorney Docket No. 26099

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

San Gabriel, et al.

Confirmation No. 4229

Serial No. 10/828,332

Art Unit: 1646

Filed: April 21, 2004

Examiner: G. CHANDRA

For: NOVEL GLUTAMIC ACID RECEPTOR AND UTILIZATION THEREOF

TRANSMITTAL LETTER

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- 1) Transmittal Letter, one (1) page; and
- 2) Amendment and Response (21) pages.

If an Extension of Time under 37 CFR §1.136 is required and has not been separately petitioned, please consider this Transmittal Letter as including a petition for such Extension of Time and as a further authorization to charge any fee for such Extension of Time, as may be required by 37 CFR §1.17, to Deposit Account No. 14-0112. Also, please charge any fee deficiency, or credit any overpayment, in connection with this matter to Deposit Account No. 14-0112.

Respectfully submitted,

Gary M. Nath


Registration No. 26,965 Susanne M. Hopkins Registration No. 33,247

Customer No. 20259

Date: April 6, 2006

NATH & ASSOCIATES PLLC 1030 15<sup>th</sup> Street,, N.W., 6<sup>th</sup> Floor

Washington, D.C. 20005 Telephone: (202) 775-8383 Facsimile: (202) 775-8396





## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

San Gabriel, et al.

Confirmation No. 4229

Serial No. 10/828,332

Art Unit: 1646

Filed: April 21, 2004

Examiner: G. CHANDRA

For: NOVEL GLUTAMIC ACID RECEPTOR AND UTILIZATION THEREOF

AMENDMENT AND RESPONSE TO FINAL OFFICIAL ACTION

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This Amendment is submitted in the above-identified application responsive to the final Official Action on the merits dated January 6, 2006, making a response due on or before April 6, 2006.

Please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 8 of this paper.

A **Conclusion** appears at page 21 of this paper.